

Iain B Squire

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5402413/publications.pdf>

Version: 2024-02-01

59
papers

6,552
citations

159585

30
h-index

133252

59
g-index

60
all docs

60
docs citations

60
times ranked

8118
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. The Cochrane Library, 2022, 2022, CD013879.	2.8	66
2	Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases. Heart, 2022, 108, 16-21.	2.9	7
3	Diagnostic accuracy of screening questionnaires for obstructive sleep apnoea in adults in different clinical cohorts: a systematic review and meta-analysis. Sleep and Breathing, 2022, 26, 1053-1078.	1.7	20
4	Developing a core outcome set for patient-reported symptom monitoring to reduce hospital admissions for patients with heart failure. European Journal of Cardiovascular Nursing, 2022, 21, 830-839.	0.9	3
5	Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography-tandem mass spectrometry-based urine analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 296-301.	3.0	12
6	Exercise Intolerance in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 397-413.	2.1	15
7	Effect of Nephilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. Circulation, 2021, 144, 199-209.	1.6	40
8	Chronic infarct size after spontaneous coronary artery dissection: implications for pathophysiology and clinical management. European Heart Journal, 2020, 41, 2197-2205.	2.2	35
9	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. European Journal of Heart Failure, 2020, 22, 2383-2392.	7.1	93
10	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424.	27.0	2,821
11	Inter-study repeatability of circumferential strain and diastolic strain rate by CMR tagging, feature tracking and tissue tracking in ST-segment elevation myocardial infarction. International Journal of Cardiovascular Imaging, 2020, 36, 1133-1146.	1.5	13
12	Risk Factors for Heart Failure. Circulation: Heart Failure, 2020, 13, e006472.	3.9	100
13	Regulatory RNAs in Heart Failure. Circulation, 2020, 141, 313-328.	1.6	133
14	20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health, The, 2019, 4, e406-e420.	10.0	82
15	A novel form of glycolytic metabolism-dependent cardioprotection revealed by PKC β and β inhibition. Journal of Physiology, 2019, 597, 4481-4501.	2.9	5
16	Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study. Clinical Research in Cardiology, 2019, 108, 940-949.	3.3	12
17	Socioeconomic status and outcomes in heart failure with reduced ejection fraction. Heart, 2018, 104, 966-967.	2.9	8
18	In-hospital worsening heart failure: a clinically relevant endpoint?. ESC Heart Failure, 2018, 5, 9-18.	3.1	16

#	ARTICLE	IF	CITATIONS
19	Patient, health service factors and variation in mortality following resuscitated out-of-hospital cardiac arrest in acute coronary syndrome: Analysis of the Myocardial Ischaemia National Audit Project. <i>Resuscitation</i> , 2018, 124, 49-57.	3.0	32
20	Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction – implications for clinical trials. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018, 20, 4.	3.3	62
21	Evidence for reduced susceptibility to cardiac bradycardias in South Asians compared with Caucasians. <i>Heart</i> , 2018, 104, 1350-1355.	2.9	7
22	British Society of Heart Failure. <i>European Heart Journal</i> , 2018, 39, 2773-2774.	2.2	1
23	Variation in outcome of hospitalised patients with out-of-hospital cardiac arrest from acute coronary syndrome: a cohort study. <i>Health Services and Delivery Research</i> , 2018, 6, 1-116.	1.4	3
24	Prognostic Role of Molecular Forms of B-Type Natriuretic Peptide in Acute Heart Failure. <i>Clinical Chemistry</i> , 2017, 63, 880-886.	3.2	16
25	Risk Factors for Nonadherence to Antihypertensive Treatment. <i>Hypertension</i> , 2017, 69, 1113-1120.	2.7	150
26	Does stress perfusion imaging improve the diagnostic accuracy of late gadolinium enhanced cardiac magnetic resonance for establishing the etiology of heart failure?. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 98.	1.7	8
27	Proenkephalin, Renal Dysfunction, and Prognosis in Patients With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 56-69.	2.8	66
28	Biomarkers and prognostication in heart failure with reduced and preserved ejection fraction: similar but different?. <i>European Journal of Heart Failure</i> , 2017, 19, 1648-1650.	7.1	4
29	Acute Heart Failure: Definition, Classification and Epidemiology. <i>Current Heart Failure Reports</i> , 2017, 14, 385-392.	3.3	217
30	Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the Prognostic Importance of Microvascular Dysfunction in Aortic Stenosis (PRIMID AS) Study. <i>European Heart Journal</i> , 2017, 38, 1222-1229.	2.2	72
31	Sacubitril/valsartan: beyond natriuretic peptides. <i>Heart</i> , 2017, 103, 1569-1577.	2.9	72
32	Comparison of global myocardial strain assessed by cardiovascular magnetic resonance tagging and feature tracking to infarct size at predicting remodelling following STEMI. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 7.	1.7	22
33	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016, 37, 3167-3174.	2.2	114
34	Distinct and complementary roles for β_1 and β_2 isoenzymes of PKC in mediating vasoconstrictor responses to acutely elevated glucose. <i>British Journal of Pharmacology</i> , 2016, 173, 870-887.	5.4	19
35	Risk Related to Pre-diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	260
36	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. <i>European Journal of Heart Failure</i> , 2015, 17, 1182-1191.	7.1	48

#	ARTICLE	IF	CITATIONS
37	Circulating microRNAs and Outcome in Patients with Acute Heart Failure. PLoS ONE, 2015, 10, e0142237.	2.5	65
38	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. European Heart Journal, 2015, 36, 1106-1114.	2.2	53
39	Growth hormone for risk stratification and effects of therapy in acute myocardial infarction. Biomarkers, 2015, 20, 371-375.	1.9	2
40	Survival in South Asian and White European patients after acute myocardial infarction. Heart, 2015, 101, 630-636.	2.9	10
41	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. Journal of the American College of Cardiology, 2015, 66, 2059-2071.	2.8	118
42	Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction. IJC Heart and Vasculature, 2015, 9, 55-62.	1.1	5
43	Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure. Health Technology Assessment, 2015, 19, 1-120.	2.8	23
44	Global myocardial strain assessment by different imaging modalities to predict outcomes after ST-elevation myocardial infarction: A systematic review. World Journal of Cardiology, 2015, 7, 948.	1.5	22
45	Resuscitated cardiac arrest and prognosis following myocardial infarction. Heart, 2014, 100, 1125-1132.	2.9	23
46	Proenkephalin and Prognosis After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 280-289.	2.8	56
47	Pro-Substance P for Evaluation of Risk in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2014, 64, 1698-1707.	2.8	17
48	Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. European Heart Journal, 2013, 34, 1404-1413.	2.2	921
49	Impact of hospital proportion and volume on primary percutaneous coronary intervention performance in England and Wales. European Heart Journal, 2011, 32, 706-711.	2.2	71
50	Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. Journal of Cardiac Failure, 2004, 10, 328-333.	1.7	151
51	N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clinical Science, 2004, 107, 309-316.	4.3	42
52	Prognosis for South Asian and white patients newly admitted to hospital with heart failure in the United Kingdom: historical cohort study. BMJ: British Medical Journal, 2003, 327, 526-531.	2.3	79
53	Plasma cardiotrophin-1 following acute myocardial infarction: relationship with left ventricular systolic dysfunction. Clinical Science, 2002, 102, 9-14.	4.3	40
54	Angiotensin converting enzyme inhibition in heart failure: clinical trials and clinical practice. Cardiovascular Drugs and Therapy, 2002, 16, 67-74.	2.6	7

#	ARTICLE	IF	CITATIONS
55	Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. <i>European Journal of Heart Failure</i> , 2001, 3, 15-19.	7.1	85
56	T-cell recognition of discrete regions of the thrombolytic drug streptokinase. <i>Clinical Science</i> , 2000, 99, 239-246.	4.3	2
57	The effect of valvular regurgitation on plasma Cardiotrophin-1 in patients with normal left ventricular systolic function. <i>European Journal of Heart Failure</i> , 2000, 2, 387-391.	7.1	20
58	The rational use of β^2 -adrenoceptor blockers in the treatment of heart failure. The changing face of an old therapy. <i>British Journal of Clinical Pharmacology</i> , 2000, 49, 1-9.	2.4	40
59	Cardiotrophin-1 protects the human myocardium from ischemic injury Comparison with the first and second window of protection by ischemic preconditioning. <i>Cardiovascular Research</i> , 2000, 48, 440-447.	3.8	46